MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ImmunoGen Company Profile (NASDAQ:IMGN)

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $13.28 (93.84% upside)

Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
Show:
DateFirmActionRatingPrice TargetActions
4/29/2016Cowen and CompanyReiterated RatingHold$8.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/29/2016RBC CapitalDowngradeOutperform -> Sector Perform$18.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016Canaccord GenuityReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Jefferies GroupReiterated RatingHold$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015OppenheimerReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015Leerink SwannLower Price TargetMarket Perform$15.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015Cantor FitzgeraldReiterated RatingHold$21.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015Morgan StanleyDowngradeEqual Weight -> Underweight$10.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit SuisseInitiated CoverageNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2014JPMorgan Chase & Co.Reiterated RatingHold$13.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 4/30/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha